China coronavirus vaccine

China coronavirus vaccine

Latest news and updates on Chinese coronavirus vaccines.

Chinese state media promotes CoronaVac despite efficacy confusion
Chinese state media is championing Sinovac’s new vaccine, focussing largely on the positives while minimizing the fact that the public release of its efficacy data has raised international eyebrows. Various regulators worldwide said they would take a close look at the data for Sinovac Biotech’s CoronaVac product, which the company’s Brazilian partner, the Butantan Institute, said on Tuesday had a roughly 50% general efficacy rate – well below the 78% reported earlier. But there was little mention in Chinese media on Thursday of the questions raised by the results. “Sinovac releases vaccine data in Brazil: 100% effective in preventing severe cases, could reduce hospitalization by 80%,” natio
Fumbled rollout puts scrutiny on Chinese coronavirus vaccine
A Chinese coronavirus vaccine has been found to have a lower efficacy rate than previously publicized, and now regulators around the world are expected to closely scrutinize the vaccine before approving it for their countries. The 50% efficacy rate is lower than the 78% number that was released by Brazil’s Butantan Institute on January 7, 2021. A series of confusing releases prompted calls from the scientific community for transparency in releasing coronavirus vaccine data. On Wednesday, Sinovac Biotech chairman Yin Weidong insisted that the data showed the vaccine, called CoronaVac, was safe and effective. He pointed out that the Brazilian study included people with “very mild symptoms” an
Chinese vaccine maker hopes to vaccinate children
A Chinese  Covid-19 vaccine developer whose product has been approved for general use on adults seeks to expand its use to children as young as three years old. The company, China National Biotec Group (CNBG), is testing how well the vaccine could induce an immune response among minors, according to a radio appearance from Zhang Yuntao, vice-president of the company. The vaccine was approved last month to be used on adults under the age of 60 after an interim analysis found it offered 79% efficacy in its phase 3 trial, conducted on the same age group.  It has also been approved for emergency or general use in several other countries, including Egypt, Jordan and the United Arab Emirates. Vac